Loading…
← CockpitCompetitor Analysis › 600329.SS Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class AOpen in the cockpit ↗

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A600329.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Tianjin-based heritage traditional-Chinese-medicine (TCM) manufacturer and retail pharmacy group.

Momentum leader 86
Mkt cap
$3.75B
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$31.4M
20-day average traded
Fwd P/E
28.5×
forward earnings
ROIC−WACC
+6.9 pp
WACC 8.8%
Hurdle
+22 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥38.30
1D-0.9%
1W-4.4%
1M-6.2%
3M+4.1%
6M-10.3%
YTD-16.1%
1Y-15.2%
ATR %2.9%
52w lowhigh24.8% off high

What Tianjin Pharmaceutical Da Ren Tang does

Tianjin-based heritage traditional-Chinese-medicine (TCM) manufacturer and retail pharmacy group.

Earns from branded traditional-Chinese-medicine pills and granules sold through pharmacies and hospitals, plus the margin on a pharmacy chain that also sells other makers' products. Herbal ingredients are the main input cost.

Products and services

  • TCM patent medicines
  • Retail pharmacy chain

Customers

  • Patients/consumers via pharmacies and hospitals

Where it sits in the supply chain

  • Health Care
  • Traditional Chinese medicine
  • TCM manufacturing + retail pharmacies

What could go right

  • TCM consumer demand growth

What could go wrong

  • Centralized procurement price pressure
  • TCM efficacy/regulatory scrutiny

Moat: narrow (brand). Century-old heritage TCM brand with established consumer trust.

Headquarters: Tianjin, China · Employees: 3,890

Named competitors

Tianjin Pharmaceutical Da Ren Tang at a glance

Size Tianjin Pharmaceutical Da Ren Tang (600329.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.75B, the 643rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.30 on 18 Nov 2026.

Performance Over six months the shares fell 10.3%, against +3.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 19 in its peer set.

Growth Revenue fell 12.8% over the last twelve months (peer median +10.3%); the operating margin is 20.4% (peer median 15.7%).

Valuation It trades at 28.5× forward earnings against a peer median of 19.9× (5th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.9 points above its cost of capital (8.8% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 104600329.SS 90
Six months, rebased to 100: Tianjin Pharmaceutical Da Ren Tang against the median of its 20 peers (local-currency closes).

Tianjin Pharmaceutical Da Ren Tang financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.67BCN¥4.86BCN¥7.23BCN¥8.17BCN¥8.19B
Revenue growth—-33%-11%0%—
Gross profitCN¥3.55BCN¥3.52BCN¥3.37BCN¥3.50BCN¥3.18B
EBITDAn/aCN¥1.04BCN¥891MCN¥892MCN¥779M
Net incomeCN¥896MCN¥2.13BCN¥2.23BCN¥987MCN¥862M
Free cash flowCN¥686MCN¥378MCN¥1.16BCN¥726MCN¥776M
Capital expenditureCN¥134MCN¥119MCN¥118MCN¥141MCN¥108M
Total debtCN¥94.9MCN¥76.9MCN¥54.8MCN¥840MCN¥939M

Quarterly statements and history in the cockpit →

Tianjin Pharmaceutical Da Ren Tang competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%ROVI000513TARSXENE688336SLSOGN6005213320128940DFTXWOCKPHARMASFZNACUTAAS1877ARQT600329.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Tianjin Pharmaceutical Da Ren Tang is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×60×ROVI000513688336OGN3320128940SFZNACUTAASARQT000100600329.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tianjin Pharmaceutical Da Ren Tang is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%ROVI000513TARS688336600521301569WOCKPHARMAARQT600329.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tianjin Pharmaceutical Da Ren Tang is the large dot.

Tianjin Pharmaceutical Da Ren Tang competitors and peer comparison

Head to head with its named competitors (600329.SS vs 600085.SS vs 000538.SZ vs 600332.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Tianjin Pharmaceutical Da Ren Tang 600329.SS$3.75B-10%-13%20%28.5×16.2%
Beijing TongRenTang 600085.SS$4.91B-12%-17%8%28.7×1.7%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Guangzhou Baiyunshan Pharmaceutical 600332.SS$4.45B-13%+1%3%12.9×-0.7%
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%16.7×-7.5%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yifeng Pharmacy Chain 603939.SS$4.84B+16%+5%10%17.2×-9.3%
Zhangzhou Pientzehuang Pharmaceutical 600436.SS$11.6B-4%-19%19%40.7×24.9%

How Tianjin Pharmaceutical Da Ren Tang compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tianjin Pharmaceutical Da Ren Tang against its 20 peers (data as of 18 Nov 2026)
Measure600329.SSPeer medianRank in peer set
1-month return-6.2%+2.6%7th lowest of 21
6-month return-10.3%+3.5%6th lowest of 19
Distance from 52-week high-24.8%-29.5%10th highest of 21
Revenue growth (TTM)-12.8%+10.3%3rd lowest of 18
Operating margin20.4%15.7%4th highest of 17
Forward P/E28.5×19.9×5th most expensive of 13
Growth the price implies (Req g, 7 yrs)16.2%3.0%5th most demanding of 13
Growth delivered (Del g)-5.8%+7.7%lowest of 13
Hurdle (Req g minus delivered)+22.0 pp-11.6 pp3rd most demanding of 13
ROIC minus cost of capital+6.9 pp+4.3 pp8th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a

Questions

Who are Tianjin Pharmaceutical Da Ren Tang's main competitors?
Named competitors: Beijing TongRenTang (600085.SS), Yunnan Baiyao Group (000538.SZ), Guangzhou Baiyunshan Pharmaceutical (600332.SS), Tasly Pharmaceutical (600535.SS), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Yifeng Pharmacy Chain (603939.SS). The cockpit's measured peer set (industry) also includes Laboratorios Farmaceuticos Rovi (ROVI.MC), Livzon Pharmaceutical (000513.SZ), Tarsus Pharmaceuticals (TARS), Xenon Pharmaceuticals (XENE), Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS), SELLAS Life Sciences (SLS).
Is Tianjin Pharmaceutical Da Ren Tang expensive compared with its peers?
On forward p/e it trades at 28.5× against a peer median of 19.9×, 5th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Tianjin Pharmaceutical Da Ren Tang stock performed?
Over six months to 18 Nov 2026 the shares returned -10.3% against +3.5% for the median peer; over one year -15.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.